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Abstract
Biobanks include biological samples and attached databases. Human biobanks occur
in research, technological development and medical activities. Population genomics
is highly dependent on the availability of large biobanks. Ethical issues must be
considered: protecting the rights of those people whose samples or data are in
biobanks (information, autonomy, confidentiality, protection of private life), assuring
the non-commercial use of human body elements and the optimal use of samples
and data. They balance other issues, such as protecting the rights of researchers
and companies, allowing long-term use of biobanks while detailed information on
future uses is not available. At the level of populations, the traditional form of
informed consent is challenged. Other dimensions relate to the rights of a group
as such, in addition to individual rights. Conditions of return of results and/or
benefit to a population need to be defined. With ‘large-scale biobanking’ a marked
trend in genomics, new societal dimensions appear, regarding communication, debate,
regulation, societal control and valorization of such large biobanks. Exploring how
genomics can help health sector biobanks to become more rationally constituted
and exploited is an interesting perspective. For example, evaluating how genomic
approaches can help in optimizing haematopoietic stem cell donor registries using
new markers and high-throughput techniques to increase immunogenetic variability
in such registries is a challenge currently being addressed. Ethical issues in such
contexts are important, as not only individual decisions or projects are concerned,
but also national policies in the international arena and organization of democratic
debate about science, medicine and society. Copyright  2003 John Wiley & Sons,
Ltd.
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Introduction
Because collections of samples offer multiple long-
term scientific interests, the use of human biologi-
cal samples as biobanks occurs in a variety of situa-
tions, from research and technological development
to medical diagnosis and therapeutic activities. The
genome-based sciences have generated numerous
needs for population studies [36]. The population
dimension of genomics is highly dependent on
the availability of large biobanks adapted to the
scale of the studies envisaged. Managing such large
biobanks has become technically feasible, but it
is important to understand the general context of
Copyright  2003 John Wiley & Sons, Ltd.
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biobanks in order to identify ethical issues that
relate to them [10,15].
Biobanking prior to the genomic era
Historically, human genetic bio-collections have
mainly been motivated by the study of diseases
(most commonly of rare diseases) and have been
more family-based than population-based [17].
Population-based collections have long existed in
the context of genetic anthropology and the history
of world populations, but these are usually aca-
demic and modestly sized. Large epidemiological
collections of biological samples have rarely been
turned towards genetic data. Genetic epidemiolo-
gists have often claimed that knowing the pop-
ulation frequencies of the polymorphisms studied
in diseases and families is an important parameter
for genetic analyses. However, it has been difficult
both to get relevant large populations and to gather
financial support for results that appeared very the-
oretical and distant from economical interests.
Consideration of issues relating to
biobanking
Issues in biobanking, which were first seen as tech-
nical issues by professionals, then as ethical con-
cerns (also mainly by professionals), are increas-
ingly being considered by regulatory authorities
and at the political level [42]. It is not only a
matter of good technical conservation of samples,
optimal database construction, and means of indi-
vidual respect or protection, but also a matter of
scientific political decision at the level of national
resource exploitation. In fact, not only scientists but
also regulatory authorities and administrative enti-
ties are considering this topic within their scope
[42]. Conferences specifically focusing on multi-
disciplinary issues in biobanking have been orga-
nized, and not only by scientists [1–5]. Several
European countries have issued specific legisla-
tions regarding biobanking (e.g. Iceland, Sweden,
France and Estonia) and several International or
National Bioethics Committees are preparing, or
have already given, opinions on this subject [30].
‘Biobanks for genomics’ has become a key issue
at the societal level.
What is a biobank?
The concept of biobank includes the biological
samples themselves (of different kinds correspond-
ing to variable conservation conditions, but all may
be sources of nucleic acids), the attached databases,
and a certain level of openness, availability and
exchange for different kinds of studies. General cat-
egories of samples are family samples, or unrelated
individuals with various degrees of identification
of the person (identified, identifiable, anonymized
or anonymous) and different kinds of information
attached to the sample (personal, medical) a pri-
ori or a posteriori (e.g. resulting from a lab test).
In addition to information attached to the sample,
there are types of information relating to a group of
people that are also important (e.g. frequencies of
markers in a population, general information about
a sampled population) [10,17].
Why are biobanks important today?
Several factors are now converging to motivate the
development of large population-based collections.
The number of available polymorphic markers is
rapidly increasing (especially SNPs) and automated
molecular techniques and bioinformatics tools are
at hand for mass screening from small amounts of
sample. Polymorphisms are often related to func-
tion and may play a role in the development of
common diseases, and in the responses of individ-
uals to treatment [33]. They may also give clues
for the development of new therapeutic molecules.
Thus, data on polymorphisms of all sorts become
of primary importance, not only to academic or
medical geneticists but also to pharmaceutical com-
panies and the biotechnology industry [6,35,37]. In
this context, the tendency has been to try to consti-
tute large population collections in various coun-
tries, with European examples in Iceland, Esto-
nia, Latvia, Sweden and the UK [8,36,38]. Private
funds, sometimes in combination with public fund-
ing, are supporting those collections that become
part of the national resources. Official recognition
and identification of biobanking activity, as well
as financial sustainability, are required. There is
a need for education in biobanking and for the
production of guidelines on the quality of collec-
tions, including the management of ethical issues.
The activity of biobanker becomes a profession and
Copyright  2003 John Wiley & Sons, Ltd. Comp Funct Genom 2003; 4: 628–634.
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requires certain modes of certification or accredita-
tion [32].
General ethical tensions in the context of
biobanking
A schematic representation of the various dimen-
sions and fields of application of biobanking is
shown in Figure 1, which underlines the gap
between the interests and individual expectations
of donors and the present development of biobank-
ing in various contexts. The tensions encountered
are often a mixture of technical and quality issues
and of philosophical/societal dimensions. Analy-
ses of such issues have been detailed elsewhere
[12,15,16,25,45] but the following can be under-
lined:
• How to protect the rights of people whose
samples and data are in the biobanks (autonomy,
confidentiality and protection of private life),
whilst allowing and encouraging research [7]?
• How to ensure the non-commercial use of human
body elements, whilst allowing the use of the
samples in the development of commercial prod-
ucts [6,37]? Samples themselves may be directly
involved in drug development, with the exten-
sion of various biotherapies (cell therapies, gene
Individual
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Figure 1. From small-scale to large-scale biobanking:
various dimensions and issues
therapies, etc.): when does a sample become a
product, a reagent?
• How to inform donors correctly when one does
not know what possible developments there
will be over time? The dimensions of informed
consent are complex in this matter [22]. Between
express consent, enlarged consent and presumed
consent, there is place for other dimensions,
such as a form of solidarity through sharing
information for a common good [18].
• How to reconcile the logic that considers sam-
ples as part of body elements in some contexts,
with that which considers samples as sources of
data, more than as a body part, in other con-
texts [30]? When does a genomic sample become
data?
• How to ensure that there is a maximum quality
of sample conservation and management, whilst
allowing easy access, without complication?
• How to optimally and openly use the samples
for the rapid progress of knowledge, whilst
protecting the rights of priority of the researchers
who constituted the collection, balancing the
need for recognition of this activity and the
interests of companies [21]? This is not trivial,
and one could think of methods of recognition
of the effort and quality of biobanking, while
opening biobank access, by setting parameters
such as biobank impact factor (BIF) [11].
• How to ensure long-term financial sustainability
whilst the use and the interests involved may
vary over time? This was one of the points of
concern that came out of a survey on biobanks
in several European countries [32].
• How to avoid potential unwanted consequences,
in terms of stigmatization of specific groups or
misuse of results?
Specific features of population genomics
related to ethics
There are specific issues when considering working
at the population level:
• Access to a healthy population, not always in
relation to medical purposes or in a medical
research context, e.g. for constructing a random
control sample, or for genomic anthropology
studies. Statistical considerations may be diffi-
cult to combine with individual freedom: can
Copyright  2003 John Wiley & Sons, Ltd. Comp Funct Genom 2003; 4: 628–634.
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sampling be truly ‘random’ and representative
and completely respect the voluntary basis and
informed consent?
• Different cultural contexts, which influence in
particular the extent of ‘non-commercial use’
definition and acceptance; it may be the rule in
certain contexts and not in others.
• Individual informed consent vs. group consent.
The traditional role of informed consent as an
expression and protection of the autonomy of
the person is challenged [50]. Generally, it was
focused on individual consent. This adjusts ade-
quately to biobank projects that concern a few
individuals or families. The concept of group
consent has been introduced for small commu-
nities or populations in a different cultural con-
text and was formulated as a protocol as early
as 1993 [31]. The collective dimension that it
implies may vary according to cultural context
and the size of the population and can be met
through a group or collective consent. But it gen-
erates the question, ‘Who speaks for the group?’.
• Working at the international level, with var-
ious regulatory texts in the various countries
[4,44]. This large variation in texts addresses
the question of the status of the biological sam-
ples, which may vary according to the con-
text: physical attribute of a person, object of
the research, object of the commercial activities.
This anthropological flexibility plays on two reg-
isters: that of the proprietary world, the category
of ‘having’, that allows exchanges, patents, vari-
ous property rights; and that of ‘being’, with the
notion of patrimonial value (individual, familial,
ethnical, national, etc.).
• If biobank use leads to the generation of pop-
ulation categorizations, how to prevent misuse
of those categorizations and how to avoid social
constructions compromising the scientific activ-
ity of categorization [24,40]?
• The kind of results to be returned and notions
of benefit sharing may be thought of at the
population level, rather than at the individual
level. How to define and ensure just return to
the populations who donated the samples?
• Sample management and database organization
are issues that combine technical and ethi-
cal considerations. Of particular importance are
the rules of access and level of openness for
exchanges of samples and data between inter-
ested parties (research groups, companies, health
services). The recent interest of industrial groups
in collected population samples, especially in the
context of pharmacogenetics studies [35,37], was
mainly unplanned at the time of sampling for
existing collections.
A very valuable effort has been made in Canada,
where reference documents on ethical princi-
ples for research in genetics, and a consent
model (with various options for different kinds of
genetic studies), have been proposed, as well as
a statement of principles on the ethical conduct
of human research involving populations [46,47]
(http://www.rmga.qc.ca).
Does large-scale biobanking change the
ethical issues involved?
A comparison with the developments in physics is
relevant, as this discipline faced a change in scale
years ago. As in physics, genomics corresponds to
a change of scale, an industrial style work organi-
zation with the use of large instrumental platforms
and the involvement of large consortia [28,43].
Such changes of scale and global approaches are
general trends of present genome sciences; this
dimension is covered by the suffix ‘–omics’ in
genomics, proteomics, etc. However, the use of
biological material and especially that of human
origin gives a specific dimension to genomics that
is not shared by physics. ‘Large-scale biobanking’
induces changes in the practical management of
ethical issues that have so far been addressed in
the context of smaller biobanks, while the ethical
principles themselves do not change. In addition,
new societal dimensions are appearing, when a
whole population (or a large part of it) is affected,
regarding communication, debate, societal control
and valorization of such large biobanks, and inte-
gration of this activity in the society at large rather
than only in the scientific community. With this
change of scale and scope in biobanking, it makes
sense to talk about ‘biobank-omics’ [13].
Building large-scale biobanks necessarily invol-
ves rethinking the ethical and legal frame of per-
sonal protection and its translation into action. For
example, the collective dimension of consent is
difficult to achieve and may be not adapted con-
ceptually for large populations. It may rather be
approached by a collective debate before the start
Copyright  2003 John Wiley & Sons, Ltd. Comp Funct Genom 2003; 4: 628–634.
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of a project and before individual consents are pur-
sued: then a person can take a decision that does not
involve only him/herself as an individual, but takes
into account the dimensions underlined through this
collective debate. One of the challenges is thus to
elaborate a debate in the frame of an ‘ethics dis-
course’ [29], in order to avoid particular interests
dominating the fair collective accord.
The case of large populations is of special rele-
vance in Europe, where several ambitious projects
have been launched with special attention to eth-
ical issues [8], but that generate controversy [9].
But in fact, the large population-based collections
are only part of the present picture of biobanking
in Europe, as was shown by a survey that collected
data from 147 institutions (mostly public or private
non-profit) in six EU countries using questionnaires
and interviews [32]. This activity is increasing in
all countries, but most collections are small; only
a few are very large. One of the issues in setting
standards is to work out how, on the one hand, the
new large-scale applications can best be organized
in respect to ethical principles [18,39], without, on
the other hand, preventing the continuation and use
of the large variety of biobanks that have proved
their value over many years [48]. Harmonizing the
framework for consent forms, further use and gene
ownership, and constructing a European view on
benefit sharing all appear to be important.
Biobanks are important for genomics,
but is genomics important for biobanks?
Can genomics help to improve the organization
or the performance of biobanks constituted and
used in the context of health services? Usually
researchers or companies in the field of genomics
see the potential uses of biobanks for meeting their
own objectives, and the application of genomics
approaches for improving existing biobanks is less
often considered. Biobanks in the form of tis-
sue collections, or haematopoietic stem cell donor
registries for transplantation [19,49] exist in the
health sector. Their organization and use could be
dramatically changed using genomics approaches.
The EU project ‘MADO’ (for Marrow Donors)
(www.euromado.org, [41]) is one example. Its
main objective is the optimization of haematopoi-
etic stem cell donor registries in Europe, by eval-
uating a number of strategies in order to increase
the adequacy of the files of potential volunteer bone
marrow donors to meet the needs of patients. Com-
patibility between donor and recipient for the major
histocompatibility complex (HLA) is a key factor
for the outcome of grafts. In 70% of cases, an HLA-
compatible familial donor is not available and an
unrelated donor has to be found [27]. As a matter
of fact, although more than 8 million HLA-typed
potential donors are registered worldwide, only cer-
tain patients can actually be transplanted; this is
partly due to the difficulty of getting an HLA-
compatible donor for each of them, given the high
polymorphism of this system [20,23,34]. One of
the problems is that some HLA types are more fre-
quent than others and become over-represented in
the registries, while rare ones remain absent. The
interest is focused especially on how to increase
the immunogenetic heterogeneity of such registries
in a cost-efficient way. The project aims at finding
ways of increasing the proportion of donors pre-
senting rare HLA combinations, in order to reduce
the inequality of chances of patients to find a donor
and to avoid spending resources on donors whose
HLA type is already in excess. The approach is
based on an evaluation of genomic techniques with
a high potential for automation and of large-scale
practice. The concept explored is a molecular filter,
that should allow the screening of potential donors,
at low cost, for the likely presence of frequent HLA
combinations. Could typing for markers in the HLA
region predict frequent or rare HLA types without
performing the expensive HLA typing, and thus
become a useful tool to choose who to then com-
pletely HLA-type? The financial resources would
accordingly be allocated in priority to HLA-type
new potential donors with a highly probable non-
frequent HLA combination in order to maximize
the chances of qualitatively enriching the registries.
The molecular approaches for such a filter include
different markers (microsatellites, SNPs) and dif-
ferent techniques (high-throughput genotyping by
sequencing, or by mass spectrometry, etc.). This
approach is combined with other approaches aimed
at elucidating sociological models underlying the
recruitment and ethical requirements. This should
allow the definition of conditions to access a diver-
sified population and the most suitable ways to
recruit donors that will secure a regular increase of
the registry diversity in full respect of transparent
donor information. The above approaches and the
economic evaluation will be considered together
Copyright  2003 John Wiley & Sons, Ltd. Comp Funct Genom 2003; 4: 628–634.
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to design integrated scenarios for both recruitment
and typing strategies. First results show that the
HLA predictive value of microsatellites could be
of interest for this application [14,26]. Genomics
could lead to important reorganization of biobank-
ing activity in this health sector, and thus all dimen-
sions, from organizational and economical ones to
ethical and sociological ones must be considered.
Such use of genomics for helping biobanks in the
health sector, combining technical, ethical and soci-
etal issues, certainly is an interesting perspective.
Conclusion
Biobanking is crucial for genomics. It is a lively
and growing activity, which has been carried out
in numerous institutions for a considerable time.
Its rather loose organization, when on a small
scale, is not adapted to forthcoming large-scale
projects. The era of large-scale biobanking intro-
duces changes in the way ethical issues must be
dealt with, especially with the involvement of large
populations as such. The new biobanking activi-
ties are triggering ethical dimensions regarding the
further use of existing collections. Exploring how
genomics can help biobanks in the health sector to
become more rationally constituted and exploited
is an open perspective. The consideration of ethical
issues in such contexts is of primary importance,
as it is related not only to individual decisions or
projects, but also to national policies in the interna-
tional arena and to the organization of democratic
debate about science, medicine and society.
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